Drug Profile
Glaucoma therapeutic
Alternative Names: IOP Lowering - AbbVieLatest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Class
- Mechanism of Action Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 05 Apr 2011 Phase-II development is ongoing in USA
- 04 Dec 2008 Phase-II clinical trials in Glaucoma in USA (Ophthalmic)